MX365331B - Anticuerpo específico contra e. coli mdr. - Google Patents

Anticuerpo específico contra e. coli mdr.

Info

Publication number
MX365331B
MX365331B MX2015008653A MX2015008653A MX365331B MX 365331 B MX365331 B MX 365331B MX 2015008653 A MX2015008653 A MX 2015008653A MX 2015008653 A MX2015008653 A MX 2015008653A MX 365331 B MX365331 B MX 365331B
Authority
MX
Mexico
Prior art keywords
antibody
mdr
specific antibody
isolated
coli specific
Prior art date
Application number
MX2015008653A
Other languages
English (en)
Other versions
MX2015008653A (es
Inventor
Nagy Gábor
Nagy Eszter
Szijárto Valéria
Magyarics Zoltán
Mirkina Irina
Guachalla Luis
Badarau Adriana
Zauner Gerhild
Lukasiewicz Jolanta
Original Assignee
Arsanis Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences Gmbh filed Critical Arsanis Biosciences Gmbh
Publication of MX2015008653A publication Critical patent/MX2015008653A/es
Publication of MX365331B publication Critical patent/MX365331B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado que se une específicamente al antígeno O25b de cepas de E. coli resistentes a múltiples fármacos (MDR), su uso médico y de diagnóstico, el método de producción del anticuerpo, incluyendo una secuencia de nucleótidos aislada, plásmidos y células huésped como se utiliza en la producción del anticuerpo; y adicionalmente un epítopo aislado reconocido por el anticuerpo específico. Figura 6.
MX2015008653A 2013-01-17 2014-01-17 Anticuerpo específico contra e. coli mdr. MX365331B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151627 2013-01-17
PCT/EP2014/050895 WO2014111516A1 (en) 2013-01-17 2014-01-17 Mdr e. coli specific antibody

Publications (2)

Publication Number Publication Date
MX2015008653A MX2015008653A (es) 2016-02-05
MX365331B true MX365331B (es) 2019-05-29

Family

ID=47552912

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008653A MX365331B (es) 2013-01-17 2014-01-17 Anticuerpo específico contra e. coli mdr.
MX2019001795A MX394233B (es) 2013-01-17 2014-01-17 Anticuerpo específico contra e. coli mdr.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019001795A MX394233B (es) 2013-01-17 2014-01-17 Anticuerpo específico contra e. coli mdr.

Country Status (19)

Country Link
US (6) US9849169B2 (es)
EP (2) EP3167903B1 (es)
JP (3) JP6553517B2 (es)
CN (1) CN105120896B (es)
AU (2) AU2014206799B9 (es)
BR (1) BR112015014991B1 (es)
CA (1) CA2895327C (es)
DK (1) DK2945651T3 (es)
ES (2) ES2718051T3 (es)
HU (1) HUE038915T2 (es)
IL (2) IL273685B2 (es)
MX (2) MX365331B (es)
NZ (1) NZ707777A (es)
PL (1) PL2945651T3 (es)
PT (1) PT2945651T (es)
RU (1) RU2711512C2 (es)
TR (1) TR201807924T4 (es)
WO (1) WO2014111516A1 (es)
ZA (1) ZA201503282B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057689A1 (en) * 2010-10-29 2012-05-03 Ge Healthcare Bio-Sciences Ab Proximity ligation technology for western blot applications
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
WO2015117711A1 (en) * 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
WO2001078787A2 (en) 2000-04-18 2001-10-25 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
RU2189253C1 (ru) * 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
ES2353814T3 (es) 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
JP4791866B2 (ja) * 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
CN101983070B (zh) 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
CA2760096C (en) * 2009-04-27 2018-10-30 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.
NO2501406T3 (es) 2009-11-19 2018-05-19
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
CA2819366A1 (en) 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
US20140336366A1 (en) 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
ES2750525T3 (es) 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
MX371513B (es) 2013-10-11 2020-01-31 Glaxosmithkline Biologicals Sa Metodos de modificacion de celulas huespedes.
WO2015117711A1 (en) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
CN107614679B (zh) 2014-12-30 2026-04-07 葛兰素史密丝克莱恩生物有限公司 用于蛋白糖基化的组合物和方法
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef

Also Published As

Publication number Publication date
BR112015014991B1 (pt) 2024-01-23
CA2895327C (en) 2021-06-01
EP2945651B1 (en) 2018-03-07
WO2014111516A1 (en) 2014-07-24
IL273685B1 (en) 2023-06-01
CN105120896B (zh) 2019-11-12
JP2019068841A (ja) 2019-05-09
TR201807924T4 (tr) 2018-06-21
BR112015014991A2 (pt) 2017-07-11
EP2945651A1 (en) 2015-11-25
JP2019068842A (ja) 2019-05-09
NZ707777A (en) 2019-12-20
ZA201503282B (en) 2016-11-30
US12274742B2 (en) 2025-04-15
AU2014206799A1 (en) 2015-05-21
PT2945651T (pt) 2018-06-12
CN105120896A (zh) 2015-12-02
ES2718051T3 (es) 2019-06-27
PL2945651T3 (pl) 2018-08-31
AU2018204437B2 (en) 2019-04-04
US10206992B2 (en) 2019-02-19
US20170087236A1 (en) 2017-03-30
ES2669420T3 (es) 2018-05-25
US20210162034A1 (en) 2021-06-03
IL273685B2 (en) 2023-10-01
US9849169B2 (en) 2017-12-26
AU2018204437A1 (en) 2018-07-12
US20230277643A1 (en) 2023-09-07
MX2015008653A (es) 2016-02-05
EP3167903B1 (en) 2018-12-26
JP2016511633A (ja) 2016-04-21
EP3167903A1 (en) 2017-05-17
MX394233B (es) 2025-03-24
AU2014206799B2 (en) 2018-04-19
AU2014206799B9 (en) 2018-05-10
DK2945651T3 (en) 2018-06-14
IL239370B (en) 2020-04-30
IL239370A0 (en) 2015-07-30
IL273685A (en) 2020-05-31
RU2015134413A (ru) 2017-02-21
US20150322138A1 (en) 2015-11-12
US20250170230A1 (en) 2025-05-29
US11529405B2 (en) 2022-12-20
US20190111121A1 (en) 2019-04-18
MX2019001795A (es) 2022-07-26
US10940191B2 (en) 2021-03-09
JP6643454B2 (ja) 2020-02-12
HUE038915T2 (hu) 2018-12-28
RU2711512C2 (ru) 2020-01-17
CA2895327A1 (en) 2014-07-24
BR112015014991A8 (pt) 2023-04-25
JP6553517B2 (ja) 2019-07-31

Similar Documents

Publication Publication Date Title
NZ707777A (en) Mdr e. coli specific antibody
TN2014000438A1 (en) Anti-fcrn antibodies
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
WO2014172046A3 (en) Gene fusions and gene variants associated with cancer
NZ700578A (en) Cross-reactive staphylococcus aureus antibody
PH12016500753B1 (en) Antibodies specific to fcrn
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
AR091098A1 (es) ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
BR112015003032A8 (pt) anticorpos isolados,ácidos nucleico isolados,célula hospedeira,método de produzir um anticorpo,imunoconjugado,formulação famacêutica,uso do anticorpo e método de tratamento de um indivíduo.
WO2015023508A3 (en) Methods for improving asthma symptoms using benralizumab
EP2928492A4 (en) Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
WO2016054053A3 (en) Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
IN2015DN02772A (es)
PL406631A1 (pl) Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie
PL401502A1 (pl) Epitop i jego zastosowanie
HK1238261A1 (en) Novel anti-mfi2 antibodies and methods of use

Legal Events

Date Code Title Description
FG Grant or registration